ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cetuximab

Also written as “cetuximab”, “RPH-002” and “Cetuximab + Irinotecan”.

Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Neoplasms · Head and Neck Neoplasms, led by 26 companies.

Drug pageCetuximab: every studyMany companies study it; this page follows only the 90 they lead. All 565 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jun 4, 200390 company-led studies, 13 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only300 open or runningphase 3since Jun 4, 2003Apr 30, 2002none ahead
Merck KGaA, Darmstadt, Germany170 open or runningphase 3since Sep 7, 2005Jul 28, 2005none ahead
Pfizerits history only53 open or runningphase 3since Oct 5, 2020Dec 1, 2010Dec 31, 2029phase 2 · NCT05226871
Bristol-Myers Squibbits history only40 open or runningphase 3since Nov 17, 2017Jan 7, 2008none ahead
Hoffmann-La Rocheits history only41 open or runningphase 2since Dec 18, 2007Jul 3, 2007Aug 31, 2030phase 1 · NCT04929223
R-Pharmits history only40 open or runningphase 3since Feb 20, 2026Sep 28, 2006none ahead
Sarah Cannon Research Instituteits history only41 open or runningphase 3since Nov 9, 2005Nov 2, 2005none ahead
Merckits history only22 open or runningphase 3since May 21, 2025May 21, 2025Mar 28, 2029phase 3 · NCT06997497
Novartisits history only20 open or runningphase 2since May 16, 2012May 24, 2007none ahead
Pierre Fabreits history only20 open or runningphase 2since Sep 17, 2018Sep 17, 2018none ahead

Also a collaborator on its studies: Ono Pharmaceutical, AstraZeneca, Prologue Research International, Sanofi and Merck, S.L., Spain.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck KGaA, Darmstadt, Germany only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Jul 28, 2005.

  1. Feb 22, 2007Phase 2 study in NeoplasmsNCT00439517 · 302 enrolled · Argentina, Australia, Austria and more
  2. Apr 19, 2007Phase 2 study in Breast NeoplasmsNCT00463788 · 181 enrolled · Australia, Austria, Belgium and more
  3. May 13, 2008Phase 3 study in Stomach NeoplasmsNCT00678535 · 904 enrolled · Argentina, Australia, Austria and more
  4. Jan 9, 2009Phase 3 study in Carcinoma, Non-Small-Cell LungNCT00820755 · 583 enrolled · Germany
  5. Mar 18, 2009Phase 2 study in Carcinoma of the Head and NeckNCT00865098 · 27 enrolled · Japan
  6. Sep 3, 2009Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT00971932 · 33 enrolled · Japan
  7. Nov 10, 2009Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT01012258 · 70 enrolled · China
  8. Jun 2, 2010Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT01177956 · 73 enrolled · China, Korea, Republic of
  9. Sep 9, 2010Phase 3 study in Colorectal NeoplasmsNCT01228734 · 553 enrolled · China
  10. Jun 24, 2011Phase 2 study in Stomach NeoplasmsNCT01388790 · 40 enrolled · Germany
  11. Oct 7, 2011Phase 2 study in Colorectal NeoplasmsNCT01450319 · 73 enrolled · Spain
  12. Mar 4, 2015Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT02383966 · 243 enrolled · Germany
  13. Oct 22, 2018Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03717155 · 43 enrolled · Hungary, Serbia, Spain
  14. Dec 9, 2018Named cetuximabINNProposed as its International Nonproprietary Name in WHO's List 120 · before, RPH-002
  15. Aug 11, 2020Phase 2 study in Colorectal NeoplasmsNCT04515394 · 3 enrolled · United States, Belgium, Czechia and more

TargetBeta

EGFR →read by rule
“A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 17 Merck KGaA, Darmstadt, Germany leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04515394Colorectal Neoplasms · United States, Belgium, Czechia and more2TerminatedMar 14, 20223
NCT03717155Carcinoma, Non-Small-Cell Lung · Hungary, Serbia, Spain2CompletedSep 30, 202043
NCT02383966Squamous Cell Carcinoma of Head and Neck · Germany3CompletedJan 19, 2018243
NCT01450319Colorectal Neoplasms · Spain2CompletedDec 201473
NCT01388790Stomach Neoplasms · Germany2CompletedAug 201240
NCT01228734Colorectal Neoplasms · China3CompletedJan 25, 2016553
NCT01177956Squamous Cell Carcinoma of Head and Neck · China, Korea, Republic of3CompletedJan 201173
NCT01012258Squamous Cell Carcinoma of Head and Neck · China3CompletedSep 201070
NCT00971932Squamous Cell Carcinoma of Head and Neck · Japan2CompletedMar 201133
NCT00865098Carcinoma of the Head and Neck · Japan2CompletedJun 201027
NCT00820755Carcinoma, Non-Small-Cell Lung · Germany3CompletedDec 2011583
NCT00678535Stomach Neoplasms · Argentina, Australia, Austria and more3CompletedMar 2012904
NCT00463788Breast Neoplasms · Australia, Austria, Belgium and more2CompletedJul 2009181
NCT00439517Neoplasms · Argentina, Australia, Austria and more2CompletedJun 2009302
NCT00154102Colorectal Neoplasms · Argentina, Australia, Austria and more3CompletedDec 20061,221
NCT00148798Carcinoma, Non-Small-Cell Lung · Argentina, Australia, Austria and more3CompletedJul 20071,861
NCT00125034Neoplasm Metastasis · Austria, Belgium, France and more2CompletedMar 2007344

How it is read

Names in the registry

  • “Cetuximab”, 57 entries
  • “cetuximab”, 11 entries
  • “RPH-002”, 2 entries
  • “Cetuximab + Irinotecan”, 2 entries
  • “Cetuximab + mFOLFOX6”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.